{'fraction_non_alphanumeric': 0.028136882129277566, 'fraction_numerical': 0.023574144486692015, 'mean_word_length': 5.178403755868545, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Prognosis of isoniazid-resistant patients of pulmonary tuberculosis].

At present, the most important regimen of tuberculosis chemotherapy is a combination of isoniazid and rifampicin combination, to which either of streptomycin, ethambutol or/ and pyrazinamide is added in the earlier stage. If isoniazid is resistant, the efficacy of this regimen is diminished. In order to confirm this fact, we investigated the prognosis of isoniazid-resistant patients of pulmonary tuberculosis, comparing with that of sensitive patients or resistant patients to the other anti-tuberculous drugs. Out 456 patients of pulmonary tuberculosis, who were admitted to our sanatorium during 3 years from 1982 to 1984, 196 were culture positive for tubercle bacilli on admission. They were composed of 128 original treatment cases and 68 re-treatment cases. All of these culture strains were assessed for the grade of resistance to various anti-tuberculous drugs, according to the sensitivity tests advocated by the Japanese Society for Tuberculosis (1% Ogawa solid media). The criterion of resistance to isoniazid was determined as follows: completely resistant to than 1 ƒÊg/ ml or higher, and incompletely resistant to 1 and 5 ƒÊg/ ml of isoniazid. In 128 original treatment cases, 7 patients (5.4%) were completely resistant and 7